Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Progressive Supranuclear Palsy (PSP): early-phase trial registry
3 of 6 indexed Progressive Supranuclear Palsy (PSP) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Progressive Supranuclear Palsy (PSP): 6 US clinical trials tracked, 3 recruiting.
Progressive Supranuclear Palsy (PSP) is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Molecular NeuroImaging, running 1 of these trials.
Enrollment posture brief
Registry condition progressive-supranuclear-palsy-psp
OPEN 3 | RECR 50% | LATE 0 | EARLY 3 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Achalasia (50% recruiting · 8 trials)
Progressive Supranuclear Palsy (PSP) lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Progressive Supranuclear Palsy (PSP) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Progressive Supranuclear Palsy (PSP) is recruiting above its size-band peers.
3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Progressive Supranuclear Palsy (PSP) research.
Molecular NeuroImaging accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Progressive Supranuclear Palsy (PSP) enrolment sits around 293 participants.
Median target enrolment is 293 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.
-
Progressive Supranuclear Palsy (PSP) splits between interventional and observational designs.
3 interventional and 3 observational studies make up this index (50% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Mayo Clinic
NCT04363684
UPenn Observational Research Repository on Neurodegenerative Disease
University of Pennsylvania
NCT04715399
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
Invicro
NCT07348276
4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2
University of California, San Francisco
NCT02966145
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
Novartis Pharmaceuticals
NCT04539041
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
Molecular NeuroImaging
NCT02103894
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Progressive Supranuclear Palsy (PSP) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Progressive Supranuclear Palsy (PSP) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Progressive Supranuclear Palsy (PSP) page
6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Progressive Supranuclear Palsy (PSP) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Molecular NeuroImaging sponsors the most Progressive Supranuclear Palsy (PSP) trials on record, review their full trial history before evaluating a specific study. See Molecular NeuroImaging's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Progressive Supranuclear Palsy (PSP) condition card totals 6 registered trials; most-linked intervention [18F]T807 ([18f]mni-777); top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.